<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240108060648N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-14</date_registration>
      <primary_sponsor>The univercity of tabriz</primary_sponsor>
      <public_title>Effect of resistance and aerobic training on dynapenia and sarcopenia</public_title>
      <acronym></acronym>
      <scientific_title>Effects of resistance and aerobic exercises training on CAF, CCR and P3NP related with sarcopenia and dynapenia in elderly</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-11-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87401</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Prevention, Randomization description: The study population will be elderly women aged 65 to 75 years in Tabriz city, who will be selected on a convenience and voluntary basis. Then 36 people will be selected and after measuring body composition indices and morphological characteristics, they will be randomly divided into 3 groups control, aerobic and resistance groups using the Random allocation software program. Then the groups will be homogenized in terms of age and then concealment will be done using sealed envelopes to prevent bias, Blinding description: Concealment will be done using sealed envelopes to prevent bias.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Sarcopenia- Dinapenya.</hc_freetext>
      <i_freetext>Intervention 1: first Intervention group:  The aerobic exercise group will perform simple aerobic activities, walking, jogging, and slow running continuously in a figure-8 pattern. The load of walking sessions will gradually increase during the training weeks. Intervention 2: Second Intervention group:  Resistance group exercises include movements that involve the main muscle groups. Each session will last about an hour, including 10 minutes of warm-up, 10 minutes of cool-down, and 40 minutes of main exercises. The movements will be performed stationary. In the first sessions, 8 movements will start in two rounds, and gradually the number of movements will increase to 10 movements in three rounds. Initially, movements will be performed for 10 to 15 repetitions, and as the sessions progress, they will reach 8 to 12 repetitions. The intensity of the movements will also range from 40 to 50 percent of 1RM (low intensity) to 60 to 80 percent of 1RM (moderate intensity). The exercises will initially start with low intensity, and then overload will be applied according to the readiness of the subjects. Intervention 3: Control group: The control group will follow their normal daily activities during this period. Subjects will be asked to refrain from exercise 48 hours before blood collection.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after being de-identified.

When:
Since 1405

To whom:
It will be available to researchers working in academic and scientific institutions.

Conditions:
Researchers can use this data

Where to obtain:
Fatemeh Baharavar

How to obtain:
By email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Baharavar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No77,babaei2,parvaz,tabriz,iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5164736931</zip>
        <telephone>+98 41 3386 2932</telephone>
        <email>baharavar.F@tabrizu.ac.ir</email>
        <affiliation>The univercity of tabriz</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Baharavar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No77,babaei2,parvaz,tabriz,iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5164736931</zip>
        <telephone>+98 41 3386 2932</telephone>
        <email>baharavar.F@tabrizu.ac.ir</email>
        <affiliation>The univercity of tabriz</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Possibility of doing sports activities
The presence of sarcopenia</inclusion_criteria>
      <agemin>65 years</agemin>
      <agemax>75 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Taking medication
Having certain musculoskeletal diseases
Underlying disease
Presence of risk factors (chest pain, heart attack in first-degree relatives, limping when walking, etc.)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>first Intervention group:  The aerobic exercise group will perform simple aerobic activities, walking, jogging, and slow running continuously in a figure-8 pattern. The load of walking sessions will gradually increase during the training weeks.</i_keyword>
      <i_keyword>Second Intervention group:  Resistance group exercises include movements that involve the main muscle groups. Each session will last about an hour, including 10 minutes of warm-up, 10 minutes of cool-down, and 40 minutes of main exercises. The movements will be performed stationary. In the first sessions, 8 movements will start in two rounds, and gradually the number of movements will increase to 10 movements in three rounds. Initially, movements will be performed for 10 to 15 repetitions, and as the sessions progress, they will reach 8 to 12 repetitions. The intensity of the movements will also range from 40 to 50 percent of 1RM (low intensity) to 60 to 80 percent of 1RM (moderate intensity). The exercises will initially start with low intensity, and then overload will be applied according to the readiness of the subjects.</i_keyword>
      <i_keyword>Control group: The control group will follow their normal daily activities during this period. Subjects will be asked to refrain from exercise 48 hours before blood collection.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Creatinine to cystatin C ratio. Timepoint: 24 hours before starting the training protocol and 48 hours after its completion. Method of measurement: Creatinine measurement using Pars Azmoun kits Tehran, Iran -Cys-C measurement using ELISA kit (BioVendor, Czech Republic).</prim_outcome>
      <prim_outcome>N-terminal propeptide of procollagen type 3. Timepoint: 24 hours before starting the training protocol and 48 hours after its completion. Method of measurement: N-terminal propeptide of procollagen type 3 kit from zellbio, Germany.</prim_outcome>
      <prim_outcome>Agrin C-terminal fragment. Timepoint: 24 hours before starting the training protocol and 48 hours after its completion. Method of measurement: Agrin C-terminal fragment kit from zellbio, Germany.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body composition index. Timepoint: 24 hours before the protocol and 48 hours after the protocol is completed. Method of measurement: Digital Arzoom scale for measuring the weight of subjects - German Seka model 769 height scale for measuring the height of tests - Body composition formula.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Fatemeh Baharavar</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-24</approval_date>
        <contact_name>Ethical committee of Tabriz University of Medical sciences</contact_name>
        <contact_address>Faculty of Physical Education and Sport Sciences, University of Tabriz, Abrassan street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
